Citizens Financial Group Inc. RI Decreases Position in Henry Schein, Inc. (NASDAQ:HSIC)

Citizens Financial Group Inc. RI trimmed its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 19.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,705 shares of the company’s stock after selling 1,135 shares during the period. Citizens Financial Group Inc. RI’s holdings in Henry Schein were worth $343,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of HSIC. Cromwell Holdings LLC boosted its holdings in Henry Schein by 93.4% during the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock valued at $26,000 after acquiring an additional 170 shares during the period. Summit Securities Group LLC bought a new stake in Henry Schein in the second quarter valued at approximately $31,000. Beach Investment Counsel Inc. PA purchased a new stake in shares of Henry Schein during the second quarter valued at approximately $37,000. Blue Trust Inc. grew its holdings in shares of Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after purchasing an additional 475 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Henry Schein by 58.9% in the third quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock worth $68,000 after purchasing an additional 346 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. The trade was a 22.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now owns 87,706 shares of the company’s stock, valued at approximately $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Henry Schein Trading Up 1.8 %

NASDAQ HSIC opened at $75.08 on Friday. The firm has a market capitalization of $9.36 billion, a PE ratio of 30.90, a P/E/G ratio of 2.12 and a beta of 0.87. The stock’s 50 day moving average is $70.89 and its 200 day moving average is $69.76. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.63. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.32 EPS. Research analysts forecast that Henry Schein, Inc. will post 4.78 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on HSIC shares. Evercore ISI increased their price target on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research report on Tuesday, October 8th. Barrington Research reiterated an “outperform” rating and set a $82.00 target price on shares of Henry Schein in a report on Wednesday, November 6th. Robert W. Baird reduced their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, UBS Group cut their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $78.89.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.